UBSI Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
UBSI is not a good buy right now for an impatient buyer. The stock is in a bullish uptrend, but it’s sitting just below near-term resistance (~43.28) with RSI already elevated and short-horizon pattern stats skewing slightly negative over the next week/month. With limited immediate upside to the nearest resistance and no fresh news catalyst, the risk/reward for buying today is only average; I prefer a pullback closer to ~41.99–40.69 for a higher-conviction entry.
Trend is bullish: moving averages are stacked positively (SMA_5 > SMA_20 > SMA_200), supporting an ongoing uptrend. Momentum is positive but cooling: MACD histogram is above zero (0.0581) yet contracting, suggesting upside momentum is still present but decelerating. RSI(6) at 66.34 is still technically neutral but close to overbought, implying less room for an immediate chase. Key levels: Pivot 41.99; support S1 40.69 (then S2 39.89). Resistance R1 43.28 (near-term ceiling) then R2 44.08. Given price ~42.33, upside to R1 is modest, so a near-term breakout needs a catalyst; otherwise, a drift/pullback is plausible.
Intellectia Proprietary Trading Signals
Strong latest quarter growth (2025/Q
with better profitability trends can continue to support the uptrend.
Recent analyst price target increases (43–47 range) provide incremental support and confirm improving Street expectations.
Options open interest skew (low put/call OI ratio) suggests more bullish positioning than bearish.
No news catalysts in the last week—harder to push through resistance without an event-driven trigger.
Price is close to resistance (43.
with cooling momentum (MACD contracting) and elevated short-term RSI, reducing the attractiveness of chasing.
Pattern-based forward stats indicate slightly negative expected performance over the next week/month (higher odds of mild drift lower).
Latest reported quarter: 2025/Q4. Revenue grew to 302.822M (+23.36% YoY), net income rose to 128.828M (+36.46% YoY), and EPS increased to 0.91 (+30.00% YoY). This is a clear acceleration in both top-line and bottom-line growth, supporting the fundamental backdrop for the stock’s recent uptrend.
Recent trend: analysts have been raising price targets following Q4 results. Keefe Bruyette lifted PT to $43 (Market Perform), Stephens lifted PT to $44 (Equal Weight), and Piper Sandler lifted PT to $47 (Overweight) citing stronger net interest income and lower credit costs, with some caution on weaker loan growth. Wall Street pros: improving earnings profile, capital/buybacks, better-than-expected quarter. Cons: mixed ratings (not universally bullish) and loan growth cited as a watch item; with the stock already near raised targets on the lower end ($43–$44), near-term upside may be constrained unless execution stays strong.
